Please assess the completion status of the following clinical trial:

Trial Title: Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Idiopathic heart failure and/or arrhythmia of less than 3 months duration~* Endomyocardial biopsy diagnostic of idiopathic giant cell myocarditis~* Negative pregnancy test~Exclusion criteria:~* Clinical evidence of sepsis or active infection (e.g., meningitis or osteomyelitis)~* Pregnant~* Any contraindication to immunosuppression~* Allergy to cyclosporine or muromonab-CD3~* Creatinine greater than 2.5 mg/dL~* AST or ALT greater than 3 times upper limit of normal~* Other severe concurrent disease that would preclude study~* Unreliable or uncooperative subject

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).